Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)

24 Dec 2021

Abstract excerpt

INTRODUCTION: Up to now, a total of eight Janus kinase (JAK) inhibitors have been approved for the treatment of autoimmune and myeloproliferative disease. The JAK family belongs to the non-receptor tyrosine kinase family, consisting of JAK1, JAK2, JAK3, and Tyk2. Among these four subtypes, only JAK3 is mainly expressed in hematopoietic tissue cells and is exclusively associated with the cytokines shared in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Pharmacological Effects of Medicinal Plants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34949146
DOI: 10.1080/13543776.2022.2023129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)PMID 34949146Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

JAK Kinases in Health and Disease: An UpdateSemantic proximity Read ↗

JAK inhibitors ∼ overview∼Semantic proximity Read ↗

Therapeutic targeting of Janus kinases.Semantic proximity Read ↗

Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literatureSemantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

The many faces of Janus kinase.Semantic proximity Read ↗

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseasesSemantic proximity Read ↗

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.Semantic proximity Read ↗

Molecular Structure and Function of Janus Kinases: Implications for the Development of InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.